3 February 2023
SHARE NOW
ATW
Automation & Digitisation
Cell Therapy
Gene Therapy
Logistics
In this Tech Demo, Title21 describes how its Manufacturing Exertion System (MES), a powerful platform of integrated modules can supports autologous and allogeneic workflows.
Title21 demonstrates the applications of the MES cell manufacturing platform whilst showing how to navigate the integrated system built for ease of customer use.
The platform offers a shortened implementation time, reduced configuration efforts and lower workflow costs, whilst providing out-of-the-box modules for evolving protocols.
This demo has been produced in partnership with Title21.
 |
 |
More like this
Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
Kite’s Yescarta CAR-T cell therapy has demonstrated significant improvement for the treatment of relapsed/refractory large B-cell lymphoma from its Phase III ZUMA trial.
23 March 2023
Pfizer Invests $43 Billion to Acquire Seagen
Pfizer is to acquire global technology company Seagan in a definitive merger agreement for a total enterprise value of $43 billion.
14 March 2023
Early Adoption and Partnerships – The Secret to Commercialization Success?
This Briefing from Advanced Therapies Week 2023 focusses on how partnerships within the industry can advance research from the clinic to manufacturing scale, to keep pace with the evolving field.
2 March 2023
Discover more like this
